Although the success of CD19 CAR T cell therapy in B-ALL has revolutionized anticancer therapy, the high rate of complete response is sometimes limited by the emergence of CD19-negative leukemia cells (27). Here, CD19 is linked to acute lymphoblastic leukemia.